Low-dose quadruple antihypertensive combination - More efficacious than individual agents - A preliminary report

被引:76
作者
Mahmud, Azra
Feely, John [1 ]
机构
[1] St James Hosp, Trinity Ctr Hlth Sci, Dept Pharmacol & Therapeut, Hypertens Clin, Dublin 8, Ireland
[2] Univ Dublin Trinity Coll, Ctr Hlth Sci, Dept Pharmacol & Therapeut, Dublin 2, Ireland
关键词
antihypertensive drugs; hypertension; antihypertensive combinations; blood pressure;
D O I
10.1161/01.HYP.0000254479.66645.a3
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Increasingly combined antihypertensive agents are being used in practice to enhance control and improve compliance. To determine whether a capsule containing a quarter of the standard dose of 4 antihypertensive agents has greater efficacy than the standard dose of each individually, we prospectively randomized 108 untreated white hypertensive patients (55% male) aged 50 +/- 1 years (mean +/- SEM), with mean blood pressure 160 +/- 1/96 +/- 1 mm Hg. Patients received amlodipine (5 mg; n=2), atenolol (50 mg; n=20), bendroflumethiazide (2.5 mg; n=22), captopril (50 mg twice daily; n=22) or a capsule containing each of the 4 above at one-quarter dosage (n=22) in a parallel group design for 4 weeks. Blood pressure was measured using a semiautomated device (Omron 705), and the reduction in mean arterial pressure with the combined preparation was compared with that of the individual components. Statistical analysis used ANOVA and Tukey - Kramer honestly significant difference for multiple comparisons. The reduction in mean arterial pressure with the combination (19 +/- 2 mm Hg) was significantly greater than that with individual agents amlodipine (10 +/- 2 mm Hg; P < 0.005), atenolol (10 +/- 2 mm Hg; P < 0.005), bendroflumethiazide (6 +/- 1 mm Hg; P < 0.005), and captopril (11 +/- 1 mm Hg; P < 0.01). In addition, the percentage reduction in systolic (18 +/- 1 mm Hg; P < 0.005) and diastolic (17 +/- 2 mm Hg; P=0.06) blood pressure was greater with the combination. More patients achieved a blood pressure of < 140/90 mm Hg with the combination (60%) than any individual drug (15% to 45%; P < 0.05). A low-dose combination of 4 agents representing 4 classes of standard antihypertensive agents was more efficacious than a standard single dose of each agent individually.
引用
收藏
页码:272 / 275
页数:4
相关论文
共 14 条
[1]   Predictors of adherence with antihypertensive and lipid-lowering therapy [J].
Chapman, RH ;
Benner, JS ;
Petrilla, AA ;
Tierce, JC ;
Collins, SR ;
Battleman, DS ;
Schwartz, JS .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) :1147-1152
[2]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[3]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906
[4]  
Dezii C M, 2000, Manag Care, V9, P2
[5]   Optimisation of antihypertensive treatment by crossover rotation of four major classes [J].
Dickerson, JEC ;
Hingorani, AD ;
Ashby, MJ ;
Palmer, CR ;
Brown, MJ .
LANCET, 1999, 353 (9169) :2008-2013
[6]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials [J].
Jones, DW ;
Hall, JE .
HYPERTENSION, 2004, 43 (01) :1-3
[7]  
Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3
[8]   Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials [J].
Law, MR ;
Wald, NJ ;
Morris, JK ;
Jordan, RE .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7404) :1427-1431
[9]   Should β blockers remain first choice in the treatment of primary hypertension?: A meta-analysis [J].
Lindholm, LH ;
Carlberg, B ;
Samuelsson, O .
LANCET, 2005, 366 (9496) :1545-1553
[10]   Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition [J].
Mahmud, A ;
Feely, J .
AMERICAN JOURNAL OF HYPERTENSION, 2002, 15 (04) :321-325